Keyphrases
Gastric Cancer
100%
Peritoneal Metastasis
100%
Gastric Cancer Cells
37%
Peritoneal Recurrence
25%
Validation Set
25%
Small Interfering RNA (siRNA)
25%
Fluorouracil
25%
Therapeutic Target
12%
Expression Level
12%
Prognostic Marker
12%
Curative Resection
12%
Therapeutic Effect
12%
Clinical Characteristics
12%
Patient Survival
12%
Quantitative PCR
12%
Novel Diagnostics
12%
Recurrence Pattern
12%
Immunohistochemical Analysis
12%
Optimal Cutoff
12%
Novel Therapeutics
12%
Recurring
12%
Adjuvant Chemotherapy
12%
Predictive Value
12%
Promising Target
12%
Transcriptome Analysis
12%
Stage II-III
12%
Intraperitoneal Administration
12%
Gastric Tissue
12%
Recurrence-free Survival
12%
PCR Analysis
12%
Advanced Gastric Cancer
12%
Gastrectomy
12%
SiRNA Knockdown
12%
Prolonged Survival
12%
Recurrence or Metastasis
12%
Curative Gastrectomy
12%
Survival Disparities
12%
Diagnostic Value
12%
Mouse Xenograft Model
12%
Stage III Gastric Cancer
12%
Micrometastasis
12%
Synaptotagmin
12%
Peritoneal Nodules
12%
Recurrent Patterns
12%
Diagnostic Targets
12%
Screening Candidates
12%
Clinical Survival
12%
Medicine and Dentistry
Peritoneum Metastasis
100%
Abdominal Cancer
100%
Cancer Cell
27%
Small Interfering RNA
27%
Diagnosis
18%
Recurrent Disease
18%
Fluorouracil
18%
Gastrectomy
18%
Biological Marker
9%
Cancer Tissue
9%
Surgery
9%
Therapy Effect
9%
Metastatic Carcinoma
9%
In Vitro
9%
Adjuvant Chemotherapy
9%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Gene Expression Profiling
9%
Intraperitoneal Drug Administration
9%
Xenograft
9%
Recurrence Free Survival
9%
Micrometastasis
9%
Synaptotagmin
9%
Messenger RNA
9%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Peritoneum Metastasis
100%
Small Interfering RNA
27%
Recurrent Disease
18%
Fluorouracil
18%
Biological Marker
9%
Chemotherapy
9%
Therapeutic Effect
9%
Recurrence Free Survival
9%
Transcriptome
9%
Synaptotagmin
9%
Micrometastasis
9%
Messenger RNA
9%
Immunology and Microbiology
Cancer Cell
100%
Xenograft
33%
Cancer Tissue
33%
Quantitative Reverse Transcription Polymerase Chain Reaction
33%
Recurrence Free Survival
33%
Gene Expression Assay
33%